Treatment of subepidermal immunobullous diseases

Clinics in Dermatology

Volumn 30, Issue 1, 2012, Pages 95-102

  Culton, Donna A ^a   Diaz, Luis A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; AZATHIOPRINE; CLOBETASOL PROPIONATE; COLCHICINE; COLESTYRAMINE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ERYTHROMYCIN; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; OMALIZUMAB; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; SULFAMETHOXYPYRIDAZINE; TACROLIMUS; TETRACYCLINE; UNINDEXED DRUG;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ANAL TENDERNESS; ANAPHYLAXIS; ANEMIA; ANUS DISEASE; ARTICLE; AUTOIMMUNE DISEASE; BASEMENT MEMBRANE; BONE MARROW SUPPRESSION; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CATARACT; CLINICAL FEATURE; CYTOPENIA; DERMATITIS; DERMATITIS HERPETIFORMIS; DERMOEPIDERMAL JUNCTION; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENCY; DRUG RESPONSE; DYSPNEA; EPIDERMOLYSIS BULLOSA ACQUISITA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLUTEN FREE DIET; HEMOLYSIS; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE; INFECTION; INFECTION RISK; KIDNEY FAILURE; LEUKOCYTE COUNT; LEUKOPENIA; LINEAR IMMUNOGLOBULIN A DISEASE; LIVER FIBROSIS; LYMPHADENOPATHY; LYMPHOMA; METHEMOGLOBINEMIA; MUCOSA; NAUSEA; NEUROPATHY; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PLASMAPHERESIS; PRIORITY JOURNAL; SIDE EFFECT; SUBEPIDERMAL IMMUNOBULLOUS DISEASE; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOSIS; TOXIC HEPATITIS; UNSPECIFIED SIDE EFFECT; VOMITING;

DERMATITIS HERPETIFORMIS; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; EPIDERMOLYSIS BULLOSA ACQUISITA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGOID, BENIGN MUCOUS MEMBRANE; PEMPHIGOID, BULLOUS; SKIN DISEASES, VESICULOBULLOUS;

EID: 83155188959     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2011.03.015     Document Type: Article

References (112)

1. Beutner E.H., Lever W.F., Witebsky E., et al. Autoantibodies in pemphigus vulgaris: response to an intercellular substance of epidermis. JAMA 1965, 192:682-688.
2. Jordon R.E., Beutner E.H., Witebsky E., et al. Basement zone antibodies in bullous pemphigoid. JAMA 1967, 200:751-756.
3. Lever W.F. Pemphigus. Medicine (Baltimore) 1953, 32:1-123.
4. Liu Z., Giudice G.J., Swartz S.J., et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995, 95:1539-1544.
5. Liu Z., Giudice G.J., Zhou X., et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997, 100:1256-1263.
6. Woodley D.T. The role of IgE anti-basement membrane zone autoantibodies in bullous pemphigoid. Arch Dermatol 2007, 143:249-250.
7. Zone J.J., Taylor T., Hull C., et al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007, 127:1167-1174.
8. Kirtschig G., Middleton P., Bennett C., et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010, CD002292.
9. Ahmed A.R., Maize J.C., Provost T.T. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977, 113:1043-1046.
10. Fine J.D. Management of acquired bullous skin diseases. N Engl J Med 1995, 333:1475-1484.
11. Hadi S.M., Barnetson R.S., Gawkrodger D.J., et al. Clinical, histological and immunological studies in 50 patients with bullous pemphigoid. Dermatologica 1988, 176:6-17.
12. Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol 1989, 20:458-461.
13. Joly P., Roujeau J.C., Benichou J., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321-327.
14. Joly P., Roujeau J.C., Benichou J., et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009, 129:1681-1687.
15. Bystryn J.C., Wainwright B.D., Shupack J.L. Oral and topical corticosteroids in bullous pemphigoid. N Engl J Med 2002, 347:143-145. author reply 145.
16. Chu J., Bradley M., Marinkovich M.P. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 2003, 139:813-815.
17. Chuh A.A. The application of topical tacrolimus in vesicular pemphigoid. Br J Dermatol 2004, 150:622-623.
18. Ko M.J., Chu C.Y. Topical tacrolimus therapy for localized bullous pemphigoid. Br J Dermatol 2003, 149:1079-1081.
19. Lebeau S., Mainetti C., Masouye I., et al. Localized childhood vulval pemphigoid treated with tacrolimus ointment. Dermatology 2004, 208:273-275.
20. Patton T., Korman N.J. Bullous pemphigoid treatment review. Expert Opin Pharmacother 2006, 7:2403-2411.
21. Wojnarowska F., Kirtschig G., Highet A.S., et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002, 147:214-221.
22. Dreno B., Sassolas B., Lacour P., et al. [Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study]. Ann Dermatol Venereol 1993, 120:518-521.
23. Morel P., Guillaume J.C. [Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study]. Ann Dermatol Venereol 1984, 111:925-928.
24. Siegel J., Eaglstein W.H. High-dose methylprednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1984, 120:1157-1165.
25. Savin J.A. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol 1979, 101:521-534.
26. Khumalo N.P., Murrell D.F., Wojnarowska F., et al. A systematic review of treatments for bullous pemphigoid. Arch Dermatol 2002, 138:385-389.
27. Burton J.L., Harman R.R., Peachey R.D., et al. Azathioprine plus prednisone in treatment of pemphigoid. Br Med J 1978, 2:1190-1191.
28. Guillaume J.C., Vaillant L., Bernard P., et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993, 129:49-53.
29. Collie-Duguid E.S., Pritchard S.C., Powrie R.H., et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999, 9:37-42.
30. Snow J.L., Gibson L.E. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995, 131:193-197.
31. Tavadia S.M., Mydlarski P.R., Reis M.D., et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000, 42:628-632.
32. Cummins D., Sekar M., Halil O., et al. Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 1996, 61:1661-1662.
33. Vazquez S.R., Rondina M.T., Pendleton R.C. Azathioprine-induced warfarin resistance. Ann Pharmacother 2008, 42:1118-1123.
34. Bohm M., Beissert S., Schwarz T., et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997, 349:541.
35. Grundmann-Kollmann M., Kaskel P., Leiter U., et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 1999, 135:724-725.
36. Grundmann-Kollmann M., Korting H.C., Behrens S., et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999, 40:957-960.
37. Nousari H.C., Griffin W.A., Anhalt G.J. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998, 39:497-498.
38. Beissert S., Werfel T., Frieling U., et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007, 143:1536-1542.
39. Kasperkiewicz M., Schmidt E. Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 2009, 6:270-280.
40. Dawe R.S., Naidoo D.K., Ferguson J. Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide. Br J Dermatol 1997, 137:826-827.
41. Itoh T., Hosokawa H., Shirai Y., et al. Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide. Br J Dermatol 1996, 134:931-933.
42. Heilborn J.D., Stahle-Backdahl M., Albertioni F., et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol 1999, 40:741-749.
43. Bara C., Maillard H., Briand N., et al. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol 2003, 139:1506-1507.
44. Dereure O., Bessis D., Guillot B., et al. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol 2002, 138:1255-1256.
45. Gurcan H.M., Ahmed A.R. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009, 161:723-731.
46. Kjellman P., Eriksson H., Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol 2008, 144:612-616.
47. Booth S.A., Moody C.E., Dahl M.V., et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992, 98:135-140.
48. Debol S.M., Herron M.J., Nelson R.D. Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 1997, 62:827-836.
49. Harvath L., Yancey K.B., Katz S.I. Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones. J Immunol 1986, 137:1305-1311.
50. Gurcan H.M., Ahmed A.R. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data. Am J Clin Dermatol 2009, 10:383-396.
51. Wolf R., Matz H., Orion E., et al. Dapsone. Dermatol Online J 2002, 8:2.
52. Coleman M.D. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993, 129:507-513.
53. Rhodes L.E., Coleman M.D., Lewis-Jones M.S. Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus. Clin Exp Dermatol 1995, 20:155-156.
54. Zhu Y.I., Stiller M.J. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001, 45:420-434.
55. Berk M.A., Lorincz A.L. The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch Dermatol 1986, 122:670-674.
56. Fivenson D.P., Breneman D.L., Rosen G.B., et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994, 130:753-758.
57. Kolbach D.N., Remme J.J., Bos W.H., et al. Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br J Dermatol 1995, 133:88-90.
58. Roujeau J.C., Guillaume J.C., Morel P., et al. Plasma exchange in bullous pemphigoid. Lancet 1984, 2:486-488.
59. Egan C.A., Meadows K.P., Zone J.J. Plasmapheresis as a steroid saving procedure in bullous pemphigoid. Int J Dermatol 2000, 39:230-235.
60. Mazzi G., Raineri A., Zanolli F.A., et al. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus Apher Sci 2003, 28:13-18.
61. Ruetter A., Luger T.A. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol 2004, 5:153-160.
62. Yu Z., Lennon V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999, 340:227-228.
63. Beckers R.C., Brand A., Vermeer B.J., et al. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995, 133:289-293.
64. Godard W., Roujeau J.C., Guillot B., et al. Bullous pemphigoid and intravenous gammaglobulin. Ann Intern Med 1985, 103:964-965.
65. Harman K.E., Black M.M. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999, 140:865-874.
66. Tappeiner G., Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989, 20:684-685.
67. Engineer L., Ahmed A.R. Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data. J Am Acad Dermatol 2001, 44:83-88.
68. Ahmed A.R. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001, 45:825-835.
69. Ahmed A.R., Dahl M.V. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003, 139:1051-1059.
70. Joly P., D'Incan M., Musette P. Rituximab for pemphigus vulgaris. N Engl J Med 2007, 356:521. author reply 522.
71. Saouli Z., Papadopoulos A., Kaiafa G., et al. A new approach on bullous pemphigoid therapy. Ann Oncol 2008, 19:825-826.
72. Hertl M., Zillikens D., Borradori L., et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008, 6:366-373.
73. Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol.
74. Peterson J.D., Chan L.S. Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the initial use to 2007. Ther Clin Risk Manag 2009, 5:1-7.
75. Schmidt E., Brocker E.B., Goebeler M. Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 2008, 34:56-64.
76. Schmidt E., Seitz C.S., Benoit S., et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007, 156:352-356.
77. Schulze J., Bader P., Henke U., et al. Severe bullous pemphigoid in an infant-successful treatment with rituximab. Pediatr Dermatol 2008, 25:462-465.
78. Fairley J.A., Burnett C.T., Fu C.L., et al. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007, 127:2605-2611.
79. Egan C.A., Zone J.J. Linear IgA bullous dermatosis. Int J Dermatol 1999, 38:818-827.
80. Wojnarowska F., Kirtschig G., Khumalo N. Treatment of subepidermal immunobullous diseases. Clin Dermatol 2001, 19:768-777.
81. Aboobaker J., Wojnarowska F.T., Bhogal B., et al. Chronic bullous dermatosis of childhood-clinical and immunological features seen in African patients. Clin Exp Dermatol 1991, 16:160-164.
82. Hernandez-Machin B., Penate Y., Baez B., et al. [Linear IgA bullous dermatosis of adults treated with colchicine]. Actas Dermosifiliogr 2006, 97:549-550.
83. Ang P., Tay Y.K. Treatment of linear IgA bullous dermatosis of childhood with colchicine. Pediatr Dermatol 1999, 16:50-52.
84. Aram H. Linear IgA bullous dermatosis. Successful treatment with colchicine. Arch Dermatol 1984, 120:960-961.
85. Banodkar D.D., al-Suwaid A.R. Colchicine as a novel therapeutic agent in chronic bullous dermatosis of childhood. Int J Dermatol 1997, 36:213-216.
86. Zeharia A., Hodak E., Mukamel M., et al. Successful treatment of chronic bullous dermatosis of childhood with colchicine. J Am Acad Dermatol 1994, 30:660-661.
87. Peterson J.D., Chan L.S. Linear IgA bullous dermatosis responsive to trimethoprim-sulfamethoxazole. Clin Exp Dermatol 2007, 32:756-758.
88. Dauendorffer J.N., Mahe E., Saiag P. Tacrolimus ointment, an interesting adjunctive therapy for childhood linear IgA bullous dermatosis. J Eur Acad Dermatol Venereol 2008, 22:364-365.
89. Marzano A.V., Ramoni S., Spinelli D., et al. Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium. J Dermatolog Treat 2008, 19:364-367.
90. Kasperkiewicz M., Meier M., Zillikens D., et al. Linear IgA disease: successful application of immunoadsorption and review of the literature. Dermatology 2010, 220:259-263.
91. Segura S., Iranzo P., Martinez-de Pablo I., et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007, 56:960-967.
92. Khan I.U., Bhol K.C., Ahmed A.R. Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy. J Am Acad Dermatol 1999, 40:485-488.
93. Caproni M., Antiga E., Melani L., et al. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol 2009, 23:633-638.
94. Damodar S., Viswabandya A., George B., et al. Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults-a report on 90 patients. Eur J Haematol 2005, 75:328-331.
95. Lee I., Barton T.D., Goral S., et al. Complications related to dapsone use for pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. Am J Transplant 2005, 5:2791-2795.
96. Sener O., Doganci L., Safali M., et al. Severe dapsone hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006, 16:268-270.
97. Talarico J.F., Metro D.G. Presentation of dapsone-induced methemoglobinemia in a patient status post small bowel transplant. J Clin Anesth 2005, 17:568-570.
98. McFadden J.P., Leonard J.N., Powles A.V., et al. Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid. Br J Dermatol 1989, 121:759-762.
99. Willsteed E., Lee M., Wong L.C., et al. Sulfasalazine and dermatitis herpetiformis. Australas J Dermatol 2005, 46:101-103.
100. Garioch J.J., Lewis H.M., Sargent S.A., et al. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994, 131:541-545.
101. Rottmann L.H. Details of the gluten-free diet for the patient with dermatitis herpetiformis. Clin Dermatol 1991, 9:409-414.
102. Ishii N, Hamada T, Dainichi T, et al. Epidermolysis bullosa acquisita: what's new? J Dermatol 37:220-30.
103. Kirtschig G., Murrell D., Wojnarowska F., et al. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003, CD004056.
104. Engineer L., Ahmed A.R. Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 2001, 44:818-828.
105. Cunningham B.B., Kirchmann T.T., Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol 1996, 34:781-784.
106. Megahed M., Scharffetter-Kochanek K. Epidermolysis bullosa acquisita-successful treatment with colchicine. Arch Dermatol Res 1994, 286:35-46.
107. Arora K.P., Sachdeva B., Singh N., et al. Remission of recalcitrant epidermolysis bullosa acquisita (EBA) with colchicine monotherapy. J Dermatol 2005, 32:114-119.
108. Meier F., Sonnichsen K., Schaumburg-Lever G., et al. Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins. J Am Acad Dermatol 1993, 29:334-337.
109. Gupta A.K., Ellis C.N., Nickoloff B.J., et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol 1990, 126:339-350.
110. Luke M.C., Darling T.N., Hsu R., et al. Mucosal morbidity in patients with epidermolysis bullosa acquisita. Arch Dermatol 1999, 135:954-959.
111. Clement M., Ratnesar P., Thirumoorthy T., et al. Epidermolysis bullosa acquisita-a case with upper airways obstruction requiring tracheostomy and responding to cyclosporin. Clin Exp Dermatol 1993, 18:548-551.
112. Woodley D.T., Briggaman R.A., Gammon W.T. Review and update of epidermolysis bullosa fsacquisita. Semin Dermatol 1988, 7:111-122.